Dana Investment Advisors Inc. decreased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 76,229 shares of the biotechnology company's stock after selling 4,373 shares during the period. Dana Investment Advisors Inc. owned 0.40% of Ligand Pharmaceuticals worth $8,168,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Barclays PLC raised its holdings in Ligand Pharmaceuticals by 20.0% in the 3rd quarter. Barclays PLC now owns 43,456 shares of the biotechnology company's stock valued at $4,349,000 after acquiring an additional 7,247 shares during the last quarter. Geode Capital Management LLC increased its stake in Ligand Pharmaceuticals by 5.5% in the third quarter. Geode Capital Management LLC now owns 428,270 shares of the biotechnology company's stock valued at $42,874,000 after purchasing an additional 22,495 shares during the last quarter. Fisher Asset Management LLC lifted its position in Ligand Pharmaceuticals by 12.4% during the third quarter. Fisher Asset Management LLC now owns 59,574 shares of the biotechnology company's stock worth $5,963,000 after buying an additional 6,555 shares during the period. Yousif Capital Management LLC lifted its position in Ligand Pharmaceuticals by 1.4% during the fourth quarter. Yousif Capital Management LLC now owns 7,193 shares of the biotechnology company's stock worth $771,000 after buying an additional 96 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Ligand Pharmaceuticals by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 163,924 shares of the biotechnology company's stock worth $16,407,000 after buying an additional 8,584 shares during the last quarter. Institutional investors and hedge funds own 91.28% of the company's stock.
Ligand Pharmaceuticals Price Performance
LGND stock traded down $1.17 during midday trading on Friday, reaching $114.83. 119,540 shares of the company's stock traded hands, compared to its average volume of 124,223. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $67.72 and a fifty-two week high of $129.90. The business has a 50-day moving average price of $114.37 and a two-hundred day moving average price of $111.64. The company has a market capitalization of $2.21 billion, a P/E ratio of 45.75 and a beta of 1.12.
Insider Activity at Ligand Pharmaceuticals
In other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 2,104 shares of the firm's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $116.37, for a total value of $244,842.48. Following the transaction, the chief financial officer now directly owns 20,647 shares of the company's stock, valued at $2,402,691.39. This trade represents a 9.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 5.90% of the company's stock.
Wall Street Analyst Weigh In
LGND has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, December 11th. Royal Bank of Canada upped their price target on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 11th. Benchmark reiterated a "buy" rating and issued a $135.00 price target on shares of Ligand Pharmaceuticals in a report on Monday, December 23rd. Finally, Barclays boosted their price objective on shares of Ligand Pharmaceuticals from $150.00 to $160.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $147.00.
Get Our Latest Research Report on Ligand Pharmaceuticals
About Ligand Pharmaceuticals
(
Free Report)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
Further Reading
Before you consider Ligand Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.
While Ligand Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
